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Abstract
The N-methyl-d-aspartate receptor co-agonist d-serine is synthesized by serine racemase and degraded by d-amino acid oxidase.
Both d-serine and its metabolizing enzymes are implicated in N-methyl-d-aspartate receptor hypofunction thought to occur in
schizophrenia. We studied d-amino acid oxidase and serine racemase immunohistochemically in several brain regions and
compared their immunoreactivity and their mRNA levels in the cerebellum and dorsolateral prefrontal cortex in schizophrenia. d-
Amino acid oxidase immunoreactivity was abundant in glia, especially Bergmann glia, of the cerebellum, whereas in prefrontal cortex,
hippocampus and substantia nigra, it was predominantly neuronal. Serine racemase was principally glial in all regions examined and
demonstrated prominent white matter staining. In schizophrenia, d-amino acid oxidase mRNA was increased in the cerebellum, and
as a trend for protein. Serine racemase was increased in schizophrenia in the dorsolateral prefrontal cortex but not in cerebellum,
while serine racemase mRNA was unchanged in both regions. Administration of haloperidol to rats did not signiﬁcantly affect serine
racemase or d-amino acid oxidase levels. These ﬁndings establish the major cell types wherein serine racemase and d-amino acid
oxidase are expressed in human brain and provide some support for aberrant d-serine metabolism in schizophrenia. However, they
raise further questions as to the roles of d-amino acid oxidase and serine racemase in both physiological and pathophysiological
processes in the brain.
Introduction
The N-methyl-d-aspartate receptor (NMDAR) is activated by binding
of the neurotransmitter glutamate and an obligatory co-agonist,
glycine or d-serine. d-Serine is proposed as the predominant
co-agonist, at least in the telencephalon (Schell et al., 1995, 1997),
consistent with evidence that it modulates cortical and hippocampal
NMDAR activity (Thiels et al., 1992; Mothet et al., 2000; Ito &
Hicks, 2001; Yang et al., 2003; Shleper et al., 2005).
NMDAR hypofunction is considered central to schizophrenia
pathophysiology (Olney & Farber, 1995; Coyle, 1996; Moghaddam,
2003), and perhaps to its genetic predisposition (Harrison & Owen,
2003; Harrison & Weinberger, 2005). Impaired d-serine function in
patients could contribute to NMDAR hypofunction, as central and
peripheral d-serine levels are reduced in schizophrenic patients
(Hashimoto et al., 2003, 2005; Yamada et al., 2005). Moreover,
co-administrationofd-serineorrelatedcompoundscanamelioratesome
symptoms of the disorder (Tsai et al., 1998; Heresco-Levy et al., 2005).
Altered d-serine in schizophrenia may be explained, in part, by
involvement of the d-serine catabolic enzyme d-amino acid oxidase
(DAO, also abbreviated to DAAO). DAO has been associated with
susceptibility to schizophrenia (Chumakov et al., 2002; Liu et al.,
2004; Schumacher et al., 2004; Corvin et al., 2007; Wood et al., 2007;
but see Yamada et al., 2005; Liu et al., 2006; Vilella et al., 2007) and
in addition, its putative activator, G72 (DAOA), also shows associ-
ation with the disorder (Chumakov et al., 2002; Detera-Wadleigh &
McMahon, 2006; Corvin et al., 2007; Li & He, 2007; Yue et al., 2007;
but also see Liu et al., 2006; Wood et al., 2007). DAO has been shown
to reduce NMDAR-mediated neurotransmission (Mothet et al., 2000)
and thus increased DAO in schizophrenia might contribute, via d-
serine decrements, to NMDAR dysfunction. Recent studies provide
some support for this notion (Kapoor et al., 2006; Bendikov et al.,
2007).
Serine racemase (SRR) synthesizes d-serine from l-serine
(Wolosker et al., 1999a, b), and thus alterations in SRR activity could
enhance or counteract the postulated role of DAO in schizophrenia. At
present, there is weak evidence that SRR itself may be a susceptibility
gene (Goltsov et al., 2006; Morita et al., 2007, but see Yamada et al.,
2005; Strohmaier et al., 2007), and evidence that its expression may be
altered in the disorder (Steffek et al., 2006; Bendikov et al., 2007).
The present study had two objectives. First, to characterize the
regional and cellular expression of DAO and SRR in human brain. For
these studies, we used immunohistochemistry and in situ hybridization
and focused on areas of relevance to schizophrenia and where DAO is
reputed to be abundant or important, namely the dorsolateral
prefrontal cortex (DPFC), hippocampus, cerebellum and substantia
nigra (Katagiri et al., 1991; Horiike et al., 1994; Schell et al., 1995;
Brannan et al., 1996; Moses et al., 1996; Wang & Zhu, 2003; Kapoor
et al., 2006; Wu et al., 2006; Kawazoe et al., 2007). Our second
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of DAO and SRR in schizophrenia. For these studies we used real-
time PCR and Western blotting as more robust methods to determine
mRNA and protein abundance, respectively, and focused on the DPFC
and cerebellum, given the reported preferential localizations of SRR
and DAO in these regions.
Materials and methods
Subjects studied
Brain tissue was collected at autopsy with consent at two centres,
Oxford and London. Demographic details of the subjects are shown in
Table 1. Schizophrenia was diagnosed from case notes according to
DSM-III-R (American Psychiatric Association, 1987) criteria. Most
cases were initially of paranoid or disorganized subtype. All patients
had received conventional antipsychotics. Control individuals had no
history of psychiatric of neurological illness. Neuropathological
assessment of all brains did not identify any neurodegenerative
abnormalities other than minor age-related changes. For further details
see Eastwood et al. (2001b). The research was approved by the
Oxfordshire Psychiatric Research Ethics Committee.
Tissue collection and processing
Blocks were collected from the DPFC (Brodmann area 9⁄46),
cerebellum, hippocampus and (for DAO only) from midbrain
containing the substantia nigra. Blocks from the Oxford series were
dissected directly at autopsy and stored at )80  C. Blocks from the
London series were dissected from previously snap-frozen coronal
brain slices at )20  C and returned to storage at )80  C. Sections
from both series were cut at 18 lm, collected on Superfrost Plus slides
(BDH Merck, Poole, UK) and stored at )80  C. From some subjects
in the Oxford series, formalin-ﬁxed parafﬁn-wax-embedded blocks
were also taken for immunohistochemistry. From these, 10-lm
sections were cut and collected on coated slides. All material was
coded and experiments carried out blind to diagnosis.
Generation of antisera to DAO
A rabbit polyclonal antibody against a C-terminal human DAO
sequence (peptide H-CGRILEEKKLSRMPPSHL-OH; N-terminal
Cys added for coupling) was produced by Cambridge Research
Biochemicals (Billingham, UK). Crude antiserum was puriﬁed by
afﬁnity chromatography on Thiopropyl Sepharose 6B derivatized with
the antigen. The concentration of anti-DAO antibody in glycine
eluates was 0.77 mg⁄mL. Speciﬁcity to DAO was tested by Western
blotting using human tissue lysates (protein medleys, Clontech, VWR
International) and recombinant N-terminally ﬂag-tagged human DAO
expressed in HEK293 cells. HEK293 cells were cultured in Minimum
Essential Medium (MEM, Gibco) supplemented with 10% fetal calf
serum and non-essential amino acids (Gibco) at 37  C and 10% CO2.
Cells were plated 1 day before transfection at 3.5 · 10
6 cells per
10-cm plate and transiently transfected with 6 lg plasmid-DNA using
Fugene 6 transfection reagent (Roche) according to the manufacturer’s
instructions. Cells were incubated with transfection mix for 38 h prior
to extraction of cell lysates for Western blotting analysis.
Western blotting
Frozen human and rat tissue sections were homogenized in suspension
buffer as described (Eastwood et al., 2001b). HEK293 cell lysates
were extracted in suspension buffer (50 mm Tris-HCl, pH 7.5,
150 mm NaCl, 10% glycerol, 1 mm EDTA, 0.8% Triton X-100) with
added ‘Complete’ protease inhibitors (Roche) and Phosphatase
inhibitor cocktail (Sigma). Immediately before electrophoresis sam-
ples were mixed 4 : 1 with 5· loading buffer [ﬁnal concentration
0.1 m Tris-chloride, 2% sodium dodecyl sulphate (SDS), 10%
glycerol, 1% b-mercaptoethanol, 0.02% Bromophenol blue]
and boiled for 10 min. Clontech protein medleys were diluted in
1· loading buffer (as above, but containing 50 mm DTT instead of
b-mercaptoethanol) and boiled for 5 min prior to electrophoresis.
Equal protein concentrations and a molecular weight marker rainbow
ladder (GE Healthcare, Buckinghamshire, UK or Bio-Rad, Hertford-
shire, UK) were fractionated in duplicate by electrophoresis on a 12%
SDS⁄polyacrylamide gel and transferred onto a polyvinyl diﬂuoride
membrane. Membranes were immersed in blocking buffer (2% non-fat
milk, 0.1% Tween
20 in phosphate buffered saline (PBS)) for 1 h
followed by an overnight incubation at 4  C with primary antibody
[SRR 1 : 500; BD Biosciences; DAO (0.25–0.75 lg⁄mL); anti-ﬂag
M2 1 : 15000; Sigma] in the same buffer. For quantitative measure-
ments, membranes were simultaneously incubated with a commer-
cially available antibody to cyclophilin (1 : 100 000; Abcam,
Cambridge, UK), which detects a band of 20 kDa to serve as a
loading control. For Western blots with Clontech protein medleys,
blots were stripped of the primary anti-DAO antibody (Re-Blot Plus
Western blot recycling kit, Chemicon, Hampshire, UK) and re-probed
with anti-actin as a loading control (1 : 10000; Chemicon).
Membranes were washed three times in blocking buffer, incubated
for 1 h with HRP-conjugated secondary antibody in blocking buffer
Table 1. Demographic details of schizophrenia patients and control individuals
Oxford series London series Combined series
Controls Patients Controls Patients Controls Patients
Number 12 12 10 9 22 21
Sex (M:F) 6 : 6 7 : 5 6 : 4 5 : 4 12 : 10 12 : 9
Age (years) 65 ± 4.3 53 ± 5.1 63 ± 6.7 62 ± 6.4 64 ± 3.7 57 ± 4.0
(Range) (25–79) (19–71) (26–85) (32–87) (25–85) (19–87)
Post-mortem interval (h) 39 ± 4.9 43 ± 5.4 38 ± 5.2 49 ± 8.2 39 ± 3.5 46 ± 4.6
(Range) (25–72) (18–76) (10–70) (22–97) (10–72) (18–97)
Brain pH 6.63 ± 0.11 6.42 ± 0.07 6.38 ± 0.12 6.36 ± 0.08 6.52 ± 0.08 6.40 ± 0.05
(Range) (6.2–7.71) (6.05–6.72) (5.9–6.97) (6.04–6.8) (5.9–7.71) (6.04–6.8)
Values are means ±SEM (and ranges). There are no signiﬁcant demographic differences between diagnostic groups in the Oxford, London or combined series. Tissue
was not available from all subjects for every experiment.
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for SRR, ﬂag-M2 and b-actin, and anti-rabbit immunoglobulin
1 : 5000, Chemicon, for DAO and cyclophilin) followed by washing
three times in PBS containing 0.1% Tween
20. Immunoreactive bands
were visualized on X-ray ﬁlm using the ‘ECL Plus’ kit (GE
Healthcare) on Kodak BioMax X-Omat AR ﬁlm (Sigma). Bands
were analysed by densitometry and optical density values for the target
immunoreactive bands normalized to those of the housekeeping gene
signals. Speciﬁcity for all antibodies in Western blotting was assessed
in control experiments where the primary antibody was omitted. For
DAO, a preadsorption control with the antigenic peptide was also
carried out.
Immunohistochemistry
The parafﬁn-wax-embedded sections were de-waxed in xylene over-
night, rehydrated in graded ethanol, and microwaved in antigen
unmasking solution (Vector Laboratories, Peterborough, UK) at
100  C for 10 min. The tissue was pretreated with 3% hydrogen
peroxide. Following the blocking of non-speciﬁc binding sites in 10%
normal horse (SRR) or goat (DAO) serum in PBS-0.3% Triton X-100
(PBS-T), sections were washed in PBS-T and incubated overnight at
4  C with primary antibody. Primary antibody concentrations were
titrated in pilot experiments for optimal detection and used as follows:
SRR (BD Biosciences, Oxford, UK) 1 : 35; DAO 1.5 lg⁄mL, except
forDPFC(3.75 lg⁄mL).Aftera30-mintreatmentwith1 : 100dilution
of biotinylated horse anti-mouse (SRR) or goat anti-rabbit (DAO)
immunoglobulin (Sigma), the antibody was localized by the avidin–
biotin–peroxidase technique using the Vectastain Elite ABC kit (Vector
Laboratories). The peroxidase reaction was demonstrated with 3,3¢-di-
aminobenzidine (DAB). Cresyl violet was used as a counterstain for
some sections. Speciﬁcity for all antibodies in immunohistochemistry
experiments was assessed in control experiments where the primary
antibody was omitted and for DAO with a preadsorption control.
In situ hybridization histochemistry
AmpliﬁedhumanDAOcDNA(400-bpfragment,base-pairs441–840of
Accession No. NM_001917) was subcloned into pGEM-T Easy Vector
(Promega, Southampton, UK) following the manufacturer’s recom-
mendations.Protocolsforriboprobeproductionandinsituhybridization
histochemistry have been previously described (Burnet et al., 1994).
Brieﬂy, riboprobes were produced by linearizing the DAO-pGEM-T
construct with appropriate restriction endonucleases and transcribing
using either SP6 or T7 promoter sites in the presence of [
35S]UTP
(1000 Ci⁄mmol).Theprobewasdilutedwithhybridizationbuffer[75%
formamide, 3· standard saline citrate (SSC), 1· Denhardt’s solution,
50 mm sodium phosphate buffer, pH 7.4, 10% dextran sulphate,
0.1 mg⁄mL sheared salmon sperm DNA and 20 mm dithiothreitol] to a
ﬁnal activity of 1.2 · 10
4 c.p.m.⁄mL. The diluted probe (200 lL) was
added to each slide of human tissue sections and covered with a glass
coverslip.Allslideswereincubatedovernightat50  CinliddedPerspex
trays lined with ﬁlter paper soaked with 3· SSC⁄75% formamide.
For post-hybridization washing, slides were ﬁrst rinsed in 2· SSC,
incubated in RNase A (20 lg⁄mL) for 30 min at room temperature,
and immersed in 2· SSC at 55  C for 10 min, 0.5· SSC at 55  C for
60 min and ﬁnally 0.5· SSC at room temperature for 10 min. Slides
were rinsed in ddH2O, dried and apposed to X-ray ﬁlm (Kodak) at
room temperature, or dipped in photographic emulsion using standard
methods (Eastwood et al., 2001b). Emulsion-dipped slides were
developed and counterstained with cresyl violet.
mRNA extraction and real-time PCR
Frozen human tissue sections (DPFC and cerebellum) were homog-
enized in TRI reagent (Sigma) according to the manufacturer’s
instructions. Total RNA concentration was determined spectrophoto-
metrically. Total RNA was treated with RNase-free DNase (Promega)
according to the manufacturer’s instructions. DNase-treated total RNA
(1–2 lg) was reverse transcribed using a high-capacity cDNA archive
kit (Applied Biosystems, Warrington, UK) and cDNA stored at
)70  C.
Real-time PCR was performed in an ABI Prism 7000 Sequence
Detector system (Applied Biosystems) using a real-time PCR kit for
SYBR Green I (Eurogentec, Southampton, UK) and 100 nm of
forward and reverse primers (Sigma) (SRR (F) AACCTAGTGAT-
GAGTCCAGAGAAA, (R) CTGGTTGGGATGTACCATGA; DAO
(F) CGCAGACGTGATTGTCAACT, (R) GGATGATGTACGGGGA-
ATTG; r18s (F) GTAACCCGTTGAACCCCATT, (R) CCATC-
CAATCGGTAGTAGCG; GAPDH (F) AAGGTGAAGGTCGGA
GTC, (R) GAAGATGGTGATGGGATTTC). The primers for DAO,
SRR and the ‘housekeeping genes’ ribosomal 18 s (r18s) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed
using Primer 3 software (http://frodo.wi.mit.edu/). Speciﬁcity of
primers for each transcript was conﬁrmed using a nucleotide–
nucleotide alignment search (http://www.ncbi.nlm.nih.gov/BLAST/).
Thermal cycling was initiated with incubation at 50  C for 2 min and
95  C for 10 min followed by 40 cycles of 95  C for 15 s, 60  C for
1 min and a melt curve analysis was performed at the end of each PCR
experiment. All reactions were run in triplicate. Pilot studies
established reaction efﬁciency and assay linearity with each primer
pair and melt curve analysis conﬁrmed speciﬁc product formation with
each primer pair. RNA samples which had not been reverse
transcribed (negative controls) were subjected to PCR in the same
assay as cDNA samples.
Fluorescence emission intensity from SYBR Green I was plotted
against Ct (cycle of threshold) values corresponding to the number of
PCR cycles. For each sample the Ct value was measured at a given
threshold of ﬂuorescence emission intensity corresponding to the
exponential phase of the PCR reaction. The abundance of target cDNA
in each sample was calculated from a standard curve and normalized
to the levels of r18s and GAPDH in the same sample.
Antipsychotic treatment in rats
Adult male Sprague–Dawley rats (Harlan-Olac, Bicester, UK) weigh-
ing 225–250 g were treated with the conventional antipsychotic
haloperidol (1 mg⁄kg⁄day; n ¼ 8) or the same volume of saline
(n ¼ 8) by intraperitoneal injection once daily for 14 days, killed and
brain tissue processed as described (Law et al., 2004). All procedures
were carried out in accordance with UK Home Ofﬁce Guidelines.
Protein was extracted from frozen brain sections and used for Western
blotting as described.
Statistical analysis
Previous studies showed that the detected abundance of some mRNAs
and proteins differed between the two brain series (Eastwood et al.,
2000, 2001a, b). In case a similar effect was seen here, Z-scores were
computed (Eastwood et al., 2001b) to allow data from the series to be
combined for analysis. We also inspected data from each series
separately (see Results). The effects of potential confounding variables
(brain pH, post-mortem interval and age) were explored using
correlations partialled for diagnosis. Effects of diagnosis were
DAO and SRR in normal and schizophrenic brain 1659
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pH, post-mortem interval and age as covariates where the correlation
was signiﬁcant (P<0.05). For data not normally distributed, the
Mann–Whitney U-test was used. To test for an effect of antipsychotic
drug treatment in rats, an independent samples t-test was used.
Results
Validation of DAO and SRR antibodies
A novel anti-DAO antibody, directed against a C-terminal human
DAO peptide, was validated by Western blotting using lysates from
HEK-293 cells over-expressing an N-terminally ﬂag-tagged human
DAO construct, containing a start codon in the ﬂag tag as well as the
DAO start codon. The antibody recognized recombinant DAO as a
double band at  39 and  42 kDa (Fig. 1A, lane 1). The lower band,
of predicted molecular weight for DAO (Gavazzi et al., 1987; Katagiri
et al., 1991; Moreno et al., 1999), probably represents transfected
untagged DAO translated from the DAO start codon, as only the
higher band, corresponding to ﬂag-tagged DAO (translated from the
ﬂag start codon), was detected with an anti-ﬂag antibody (Fig. 1A,
lane 3) and HEK-293 cells do not express endogenous DAO (mock-
transfected cells; Fig. 1A, lanes 2 and 4).
In order to conﬁrm that the anti-DAO antibody could detect
endogenous DAO in human tissue samples, human protein medleys
from different brain regions and peripheral tissues were analysed by
Western blotting. A strong single band at approximately  39 kDa was
detected in tissues reportedly expressing high levels of DAO
(cerebellum, spinal cord and kidney; Katagiri et al., 1991; Horiike
et al., 1994) (Fig. 1B). Anti-DAO detected a similar band in our
extracts of frozen human and rat cerebellar tissue (Fig. 1C, lanes 1–2),
and preadsorption of the DAO antibody with antigenic peptide
abolished this band (Fig. 1C, lanes 3–4). In human DPFC extracts,
detection of DAO by Western blotting was extremely variable and
sometimes absent, despite trying a range of antibody and protein
concentrations (data not shown). Similarly, in rat frontal cortex, DAO
could not be detected by Western blotting (data not shown).
SRR was detected as a single band of predicted molecular weight,
 38 kDa (Wolosker et al., 1999b; De Miranda et al., 2000), in human
and rat cerebellum (Fig. 1C, lanes 5–6) and in human DPFC and rat
prefrontal cortex (data not shown). Omission of primary antibody
abolished SRR immunoreactivity (data not shown).
The housekeeping genes cyclophilin and b-actin were detected as
single bands of predicted molecular weights of  20 and  43 kDa,
respectively (Fig. 1B and C).
In immunohistochemistry experiments, omission of the SRR
primary antibody, and preadsorption of the DAO antibody with
the antigenic peptide, abolished immunolabelling (see below; Figs 2J
and 3F).
Regional and cellular expression of DAO in the human brain
DAO was detected by immunohistochemistry in all regions examined,
but the cell types and staining intensity differed between regions.
DPFC
In the DPFC grey matter, DAO immunoreactivity was predominantly
neuronal (Fig. 2A), and visible throughout the cytoplasm of pyramidal
neuron cell bodies, sometimes granular, and surrounding unstained
nuclei (Fig. 2B). Granular immunostaining may reﬂect peroxisomal
DAO (Arnold et al., 1979; Moreno et al., 1999). Punctate spots of
immunoreactivity were also visible throughout the neuropil (Fig. 2B).
Immunolabelling of small round cells was visible in some cases
(Fig. 2B); given their size they may be glia, or, alternatively,
interneurons. In DPFC white matter, immunostaining was weak, but
moderate punctate DAO immunoreactivity was visible in addition to
the labelling of small round cells, sometimes demonstrating a peri-
cellular enhancement in their staining (Fig. 2B, inset). Again the exact
identity of these cells is unknown, but based on their size, morphology
and location, they are putatively identiﬁed as glia.
In situ hybridization and emulsion dipping of DPFC sections
revealed DAO mRNA signals clustered over pyramidal neurons with
minimal labelling of sense control sections (Fig. 2C and 2C¢). In the
white matter DAO mRNA signals were marginal (data not shown).
Hippocampus
DAO immunoreactivity in the hippocampus was principally localized
to the stratum pyramidale of Ammon’s horn and in some cases to the
dentate gyrus granule cell layer (Fig. 2D). Pyramidal neurons in CA1
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A
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Fig. 1. Detection of DAO and SRR. (A) Validation of DAO antibody using recombinant ﬂag-DAO expressed in HEK293 cells. Detection with anti-DAO (lanes 1
and 2) and anti-ﬂag (lanes 3 and 4). Flag-DAO is detected as a  42-kDa band with anti-DAO (lane 1) and anti-ﬂag (lane 3) in ﬂag-DAO transfected HEK293 cells
but not mock transfected cells (lanes 2 and 4). Expressed untagged DAO is detected as a  39-kDa band, of predicted size for DAO, with anti-DAO antibody (lane 1
lower band) but not anti-ﬂag (lane 3). (B) Validation of DAO antibody using human tissue samples (Clontech protein medleys); lane 1, cerebellum; lane 2,
amygdala; lane 3, hippocampus; lane 4, thalamus; lane 5, spinal cord; lane 6, lung; lane 7, heart; lane 8, kidney. A speciﬁc signal for DAO was detected at  39 kDa
in the cerebellum, spinal cord and kidney. Blots were re-probed with anti-b-actin as a loading control (lower panel). (C) Representative Western blots of DAO (lanes
1 and 2), DAO pre-adsorption control (lanes 3 and 4), and SRR (lanes 5–6) in protein extracts of post-mortem cerebellar tissue from human (lanes 1, 3 and 5) and rat
(lanes 2, 4 and 6). DAO was detected at  39 kDa and SRR at  38 kDa. Blots were simultaneously probed for cyclophilin as a loading control (lower band), which
was detected at  20 kDa.
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European Journal of Neuroscience, 26, 1657–1669Fig. 2. Regional and cellular distribution of DAO in the human brain. (A) DAO immunoreactivity in the DPFC demonstrating an enhancement of labelling in the
grey matter (gm) compared with the white matter (wm). (B) DAO immunoreactivity in DPFC grey matter demonstrating immunolabelling of pyramidal neurons
(*), throughout their cell bodies, and sometimes granular. Punctate spots of immunolabelling are seen throughout the neuropil (arrows), in addition to the labelling of
occasional small round cells (arrowhead). Inset: DAO immunoreactivity in the white matter as punctate spots of ﬁbre labelling and moderate staining of numerous
small round cells, often with peri-cellular enhancement (*). (C) Emulsion dipped antisense in situ hybridized DPFC sections showing localization of DAO mRNA
to pyramidal cells (arrows). (C¢) Corresponding image after sense probe hybridization. (D) DAO immunoreactivity in the hippocampus, demonstrating labelling
predominantly in neuronal subﬁelds ca1–4 and (in some cases) in the granule cells of the dentate gyrus (dg). (E) DAO immunoreactivity in ca1 pyramidal neurons.
(F) Dentate gyrus, showing moderate staining of granule cells (dg). (G) Cerebellar DAO immunoreactivity showing localization predominantly to the Purkinje cell
layer (pcl) with moderate immunolabelling in the molecular layer (ml), granule cell layer (gcl) and white matter (wm). (H) DAO immunoreactivity in the cerebellum
demonstrating strongly immunopositive putative Bergmann glia (arrows) in the Purkinje cell layer (pcl) with unstained Purkinje cells (*). In the molecular layer (ml)
moderate immunolabelling of putative Bergmann glia radial processes (rp) can be seen. (I) Cerebellar DAO immunoreactivity localized to small round cells of
similar size in the molecular layer (arrow a), granule cell layer (arrow b) and white matter (arrow c). Often these cells showed peri-cellular enhancement in staining
(inset). (J) Pre-adsorption control for DAO immunohistochemistry in the cerebellum. (K) Emulsion dipped antisense in situ hybridized sections demonstrating
silver grains clustered over putative Bergmann glia (arrows) but not over Purkinje cells (*) or the granule cell layer (gcl). (L) DAO immunoreactivity in the
substantia nigra pars compacta localized to large neurons and to some small round cells, putatively glia (arrows). Cresyl violet-stained sections (inset) demonstrate
lipofuscin in neurons (arrow). Scale bars ¼ 1 mm (A), 0.5 mm (D, G), 50 lm (B, C, C¢, E, F, H–L).
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regions displayed moderate neuronal labelling but staining appeared
less intense than in CA1 (data not shown). DAO immunoreactivity
was visible throughout pyramidal cell bodies, sometimes granular or
peri-cellular, while the nucleus was unlabelled (Fig. 2E). In the dentate
gyrus, immunoreactivity was variable; half the cases studied demon-
strated moderate to strong immunoreactivity of granule cells (Fig. 2F),
while the remainder demonstrated marginal or no immunostaining
(data not shown).
In situ hybridization and emulsion dipping of hippocampus sections
revealed DAO mRNA signals clustered over pyramidal neurons in the
CA subﬁelds, while signals in other regions were low (data not
shown).
Cerebellum
DAO immunoreactivity in the cerebellum was localized predomi-
nantly to the Purkinje cell layer (Fig. 2G), and therein to small round
cells, which, given their size and location, are putative Bergmann glia
(Fig. 2H). The Purkinje cells themselves were unlabelled (Fig. 2H).
Processes traversing the molecular layer were also immunoreactive,
some of which appeared to arise from Bergmann glia, putatively their
radial processes (Fig. 2H). The molecular layer also demonstrated
occasional immunolabelling of small round cells (Fig. 2I). In the
granule cell layer, Golgi cells and granule cells were unlabelled, but
scattered small round cells, somewhat larger than granule cells, were
immunoreactive (Fig. 2I). Cells of the white matter, with a similar
shape and size to those labelled in the molecular and granule cell
layers, were also immunoreactive (Fig. 2I). While the speciﬁc identity
of these molecular, granule cell and white matter layer cells is
unknown, their size, morphology and location suggest they are glia,
although the molecular layer cells could also be basket⁄stellate cells.
At the subcellular level, some moderately stained cells, particularly
those in the granule cell layer, demonstrated a peri-cellular enhance-
ment of immunolabelling (Fig. 2I, inset).
In situ hybridization and emulsion dipping of cerebellar sections
revealed DAO mRNA signals primarily clustered over small round
cells in the Purkinje cell layer, putatively Bergmann glia (Fig. 2K).
There were few silver grains over the Purkinje cells themselves
(Fig. 2K).
Substantia nigra pars compacta
In midbrain sections, cresyl violet staining revealed large, putatively
dopaminergic, neurons containing melanin pigment within the
substantia nigra pars compacta (Fig. 2L, inset). DAO immunoreac-
tivity was strong in these neurons, and, in cases with stronger
immunostaining, immunolabelling of putative glia was also observed
(Fig. 2L).
Regional and cellular expression of SRR in the human brain
DPFC
SRR immunolabelling in the DPFC was more abundant in the white
matter compared with the grey matter (Fig. 3A). In the grey matter,
immunolabelled small round cells were observed amongst unlabelled
cortical pyramidal neurons (Fig. 3B). In the white matter, immunola-
belling of similar small round cells, more prevalent than those in the
Fig. 3. Regional and cellular distribution of SRR immunoreactivity in the human brain. (A) DPFC, demonstrating an enhancement of staining in white matter
(wm) over grey matter (gm). (B) SRR immunoreactivity with cresyl violet counterstaining in DPFC grey matter, demonstrating immunolabelling of putative glia
(arrows) amongst immunonegative pyramidal neurons (purple). (C) SRR immunoreactivity in the DPFC white matter localized to putative glia and as punctate
white matter labelling. Inset: high-power image of SRR immunoreactivity in the hippocampal white matter. (D) SRR immunoreactivity in the cerebellum in the
white matter (wm), granule cell layer (gcl), Purkinje cell layer (pcl) and molecular layer (ml). (E) SRR immunoreactivity in the cerebellum localized to Bergmann
glia of the Purkinje cell layer (arrows a) and their radial processes (rp) in the molecular layer, putative glia of the granule cell layer (arrows b) and putative glia of the
molecular layer (arrows c). Purkinje cells were occasionally moderately immunolabelled (inset). (F) Control section after omission of primary antibody. Scale
bars ¼ 1 mm (A), 0.5 mm (B), 50 lm (C–F).
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labelling (Fig. 3C). These cells frequently demonstrated a punctate or
peri-cellular enhancement in immunostaining (Fig. 3C). Based on their
size, location and morphology they are putatively identiﬁed as glia.
Hippocampus
Similar to the DPFC, SRR immunoreactivity in the hippocampus was
predominantly localized to the white matter, including the alveus, and
concentrated over small round cells in addition to punctate immuno-
staining (Fig. 3C, inset).
Cerebellum
SRR immunoreactivity in the cerebellum was seen in all layers
(Fig. 3D). In the Purkinje cell layer, small round cells situated between
Purkinje cells were strongly immunolabelled (Fig. 3E). Their size and
location suggest they are putative Bergmann glia. The Purkinje cells
were occasionally moderately immunolabelled (Fig. 3E, inset). In the
molecular layer, there was moderate immunolabelling of putative
Bergmann glia radial processes; additionally, small round cells,
potentially basket⁄stellate or glial cells, were immunolabelled
(Fig. 3E). Throughout the granule cell layer, scattered strongly
immunopositive cells, slightly larger than granule cells, were observed
(Fig. 3E). No cells with an appearance suggestive of Golgi cells were
labelled. In the white matter, there was abundant and strong
immunostaining of small round cells (data not shown). The immu-
nolabelled cell types in these layers were observed to have a peri-
cellular enhancement in immunolabelling (data not shown) and are
presumed to be glia. The strong immunoreactivity of the cerebellar
white matter also arose from punctate immunostaining (data not
shown).
DAO expression in schizophrenia
Cerebellar DAO mRNA levels normalized to r18s correlated with
brain pH (P ¼ 0.048). No other effects of brain pH, age or post-
mortem interval were seen. DAO mRNA was increased in patients
with schizophrenia compared with control individuals whether
normalized to r18s (F1,26 ¼ 10.01, P ¼ 0.004) (Fig. 4A) or GAPDH
mRNA (data not shown). DAO immunoreactivity in the cerebellum
showed a trend to being increased in schizophrenia (F1,28 ¼ 3.79,
P ¼ 0.062) (Fig. 4B and H).
In the DPFC, DAO mRNA normalized to r18s was unchanged in
schizophrenia (Mann–Whitney U-test, P ¼ 0.33) (Fig. 4C) as was
DAO mRNA normalized to GAPDH (data not shown). In the DPFC,
because DAO immunoreactivity was extremely variable and most
subjects expressed levels of DAO protein undetectable by Western
blotting, no quantiﬁcation was attempted.
The direction of change in DAO mRNA and protein in the
cerebellum in schizophrenia was consistent between the two brain
series, but the increase in schizophrenia appeared more marked in the
London series (Table 2).
SRR expression in schizophrenia
No effects of age, brain pH or post-mortem interval were seen on SRR
mRNA and protein measurements. In the cerebellum, SRR mRNA
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Fig. 4. DAO and SRR expression schizophrenia. (A) Real-time PCR analysis of DAO mRNA normalized to r18s in the cerebellum. **P < 0.005.
(B) Western blot analysis of DAO immunoreactivity normalized to cyclophilin (Cyc) in the cerebellum. (C) Real-time PCR analysis of DAO mRNA normalized to
r18s in the DPFC. (D) Real-time PCR analysis of SRR mRNA normalized to r18s in the cerebellum. (E) Western blot analysis of SRR immunoreactivity
normalized to cyclophilin (Cyc) in the cerebellum. (F) Real-time PCR analysis of SRR mRNA normalized to r18s in the DPFC. (G) Western blot analysis of SRR
immunoreactivity normalized to cyclophilin (Cyc) in the DPFC. *P < 0.05. (H) Representative Western blots for DAO in the cerebellum and SRR in the DPFC
(upper bands) of patients with schizophrenia (S) and control subjects (C). The lower band shows the loading control cyclophilin.
DAO and SRR in normal and schizophrenic brain 1663
ª The Authors (2007). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience, 26, 1657–1669was unchanged in schizophrenia, whether normalized to r18s
(F1,27 ¼ 1.05, P ¼ 0.32) (Fig. 4D) or GAPDH mRNA (data not
shown). SRR immunoreactivity in the cerebellum was also unchanged
in schizophrenia (F1,30 ¼ 0.22, P ¼ 0.64) (Fig. 4E). In the DPFC,
SRR mRNA was unchanged in schizophrenia whether normalized to
r18s (F1,25 ¼ 0.002, P ¼ 0.96) (Fig. 4F) or GAPDH mRNA (data not
shown). SRR immunoreactivity in the DPFC was increased in
schizophrenic patients compared with control individuals (Mann–
Whitney U-test, P ¼ 0.027) (Fig. 4G and H). This effect was
consistent between the Oxford and London series (Table 2).
DAO and SRR protein in the rat brain following haloperidol
administration
DAO immunoreactivity, in the rat cerebellum was unaffected by
haloperidol (saline ¼1.27 ± 0.14 (mean ± SEM), haloperidol ¼
1.58 ± 0.35, t(14) ¼ )0.817, P ¼ 0.428). Values were normalized to
cyclophilin immunoreactivity. We could not detect DAO immunore-
activity in the frontal cortex. Haloperidol had no effect on SRR
immunoreactivity, normalized to cyclophilin, in the cerebellum (saline
¼1.56 ± 0.15, haloperidol ¼1.60 ± 0.16, t(13) ¼ )0.169, P ¼ 0.869)
or frontal cortex (saline ¼0.83 ± 0.04, haloperidol ¼0.84 ± 0.06,
t(14) ¼ )0.147, P ¼ 0.885).
Discussion
This study investigated the regional and cellular expression in human
brain of the enzymes responsible for the degradation (DAO) and
synthesis (SRR) of d-serine. It also examined whether the expression
of these enzymes was altered in the DPFC or cerebellum in
schizophrenia, a disorder in which both enzymes have been
implicated as part of a broader abnormality in NMDA receptor-
mediated signalling. Our main ﬁndings are that: (1) DAO and SRR
are expressed widely in adult human brain, in discrete but
overlapping cell populations (Table 3). DAO localized to glia in
the cerebellum, but in the cerebral cortex was predominantly
neuronal. In all regions examined, SRR immnuoreactivity was
principally glial, and was more abundant in white matter. (2) In
schizophrenia, DAO mRNA was increased in the cerebellum, and
SRR increased in the DPFC. These ﬁndings have implications for
our understanding of the cellular basis of d-serine metabolism and
for the roles of DAO and SRR in the normal brain, as well as for
their involvement in schizophrenia.
DAO expression in human brain
DAO immunoreactivity and mRNA were robustly detected in the
cerebellum, in keeping with previous studies of its expression and
activity in human (Kapooret al., 2006) and rodent cerebellum (Katagiri
et al., 1991; Horiike et al., 1994; Schell et al., 1995; Moreno et al.,
1999; Wang & Zhu, 2003; Yoshikawa et al., 2004b). Cerebellar DAO
expression, both mRNA and immunoreactivity, was primarily localized
to Bergmann glia (Fig. 2H). Immunoreactivity also localized to other
small round cells scattered in the molecular, granule cell and white
matter layers that we assume are glia (Fig. 2I). These observations are
consistent with previous immunocytochemical (Moreno et al., 1999)
and histochemical (Horiike et al., 1987) ﬁndings in the rat brain.
Morenoetal.(1999)alsoreportedDAOimmunoreactivity inGolgiand
Purkinje cells, which we did not observe in the human cerebellum. This
may be due to a species difference in DAO expression, as is seen for
other aspects of DAO biology (Pollegioni et al., 2007). Alternatively,
the discrepancy may be attributable to the antibody used by Moreno
et al. (1999), which subsequent data suggest may cross-react with
d-aspartate oxidase (Shleper et al., 2005), itself abundantly expressed
in Golgi and Purkinje cells of the rat (Zaar et al., 2002).
The situation regarding DAO in the forebrain has been less clear.
Our data conﬁrm that DAO is unequivocally expressed, both as
mRNA and as protein, in the human cerebral cortex (DPFC and
hippocampus), and also show that this is mainly neuronal with a small
Table 3. Cellular proﬁle of DAO and SRR immunoreactivity in the human
brain
DAO SRR
Cerebellum
Purkinje cells 0 + ⁄ –
Molecular layer cells* + +
Granule cells 0 0
Golgi cells 0 0
Bergmann glia +++ +++
Other glia ++ +++
Molecular layer neuropil + +
Granule cell layer neuropil + ⁄ –+ ⁄ –
White matter neuropil + ⁄ –+ +
DPFC
Pyramidal neurons +++ 0
Grey matter glia + ++
White matter glia + +++
Grey matter neuropil + + ⁄ –
White matter neuropil + +++
Hippocampus
Dentate gyrus granule cells + ⁄ –0
Pyramidal neurons +++ 0
Glia + ⁄ –+ +
Grey matter neuropil 0 + ⁄ –
White matter neuropil 0 +++
Substantia nigra pars compacta
Dopamine neurons +++ n.d.
Glia + ⁄ – n.d.
Neuropil 0 n.d.
Immunoreactivity: 0, absent; + ⁄ –, weak and variable; +, weak; ++, moderate;
+++, strong; n.d., not determined. *Stellate ⁄ basket or glia.
Table 2. DAO and SRR expression in the DPFC and CB in schizophrenia
divided by origin of tissue
Oxford series London series
Controls Patients Controls Patients
DAO (n ¼ 6–9) (n ¼ 7–8) (n ¼ 6–7) (n ¼ 6)
mRNA
CB 7.65 ± 1.11 9.69 ± 1.43 11.74 ± 0.86 15.97 ± 1.29
DPFC 8.70 ± 2.77 6.99 ± 0.90 4.335 ± 2.52 9.38 ± 3.69
Protein
CB 0.53 ± 0.06 0.60 ± 0.08 1.96 ± 0.44 3.40 ± 0.47
DPFC n.d. n.d. n.d. n.d.
SRR (n ¼ 6–8) (n ¼ 6–10) (n ¼ 7–9) (n ¼ 6–9)
mRNA
CB 1.18 ± 0.33 1.02 ± 0.21 1.10 ± 0.16 0.89 ± 0.15
DPFC 1.02 ± 0.13 0.71 ± 0.17 0.95 ± 0.16 1.27 ± 0.10
Protein
CB 0.63 ± 0.08 0.70 ± 0.09 0.79 ± 0.05 0.66 ± 0.07
DPFC 0.68 ± 0.08 0.88 ± 0.06 0.48 ± 0.06 0.59 ± 0.07
Values are means ± SEM. mRNA normalized to r18s; protein normalized to
cyclophilin. n.d., not determined.
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of the rat study by Moreno et al. (1999), but unlike the situation in
cerebellum. These ﬁndings raise three issues worthy of mention. First,
our antibody did not reliably detect DAO protein by Western blotting
in DPFC (or in hippocampus), even though it did in cerebellum, but
worked reliably for immunohistochemistry in all areas. Its speciﬁcity
for DAO is not questioned by this failure, given the experimental
controls and corroboration of the immunohistochemical data in DPFC
by our in situ hybridization ﬁndings, but it does require explanation.
Most likely, there is a regional difference in the antigenicity of DAO,
possibly consequent to differences in post-translational modiﬁcation
or conformation, which is differentially affected by Western blotting
and immunohistochemical protocols. Whether this is related to the fact
that cerebellum and cerebral cortex predominantly express DAO in
different cell types (glia vs. neurons), or the fact that cerebellum
contains a DAO transcript variant not detectable in cortex (Kapoor
et al., 2006), is unknown. Of note, Bendikov et al. (2007) did robustly
detect DAO by Western blotting in the human parietal cortex, using an
antibody raised against puriﬁed hog DAO, whereas ours was
generated against a speciﬁc peptide sequence. Potentially, their
antibody may have been less susceptible to any inter-regional
differences in DAO sequence, conformation or structure.
The second issue relates to the fact that cortical DAO immunore-
activity was mainly neuronal, whereas it was largely, if not
exclusively, glial in the cerebellum. The basis for, and signiﬁcance
of this is unclear. In the DPFC, it implies that much d-serine
catabolism is neuronal rather than glial, consistent with the recent
observations that the major d-serine transporter, Asc-1, is also
predominantly neuronal (Helboe et al., 2003; Matsuo et al., 2004;
Rutter et al., 2007). Together with the localization of SRR (Table 3),
the ﬁndings suggest that, in the cortex, d-serine is synthesized mainly
in glia, but degraded in neurons.
The third question concerns why cortical DAO expression is robust,
but cortical DAO activity is virtually undetectable (Katagiri et al.,
1991; Horiike et al., 1994; Schell et al., 1995; Wang & Zhu, 2003;
Kapoor et al., 2006). One possibility is that cortical DAO is inactive,
perhaps a remnant from an earlier, developmental function, although
its robust prolonged expression argues against this. Or, perhaps
cortical DAO has a substrate other than d-serine, and catalyses a
reaction not detected by the commonly used functional assay.
However, if this were the case, it would raise the alternative question
of how d-serine is degraded in the cortex.
DAO immunoreactivity was strong in putative dopaminergic
neurons of the substantia nigra pars compacta, consistent with an
observation in the rat (Moreno et al., 1999). This ﬁnding is of clinical
signiﬁcance given the demonstration that DAO can oxidize d-DOPA
in an alternative pathway for dopamine synthesis, and the suggestion
that d- and l-DOPA may be combined therapeutically for the
treatment of Parkinson’s disease (Brannan et al., 1996; Moses et al.,
1996; Wu et al., 2006; Kawazoe et al., 2007). However, the presence
of endogenous d-DOPA or other d-isomers of catecholamine precur-
sors in mammals is, to our knowledge, unknown. Nevertheless, the
presence of DAO in these neurons suggests that it may play a role in
dopaminergic function and, speculatively, the involvement of dopa-
mine or dopamine–glutamate interactions in schizophrenia (Laruelle
et al., 2003).
SRR expression in human brain
SRR expression was detected in the DPFC and hippocampus,
consistent with previous studies in rodent (Wolosker et al., 1999a;
Wang & Zhu, 2003; Yoshikawa et al., 2004a; Kartvelishvily et al.,
2006), primate (Xia et al., 2004) and human (Steffek et al., 2006;
Bendikov et al., 2007). Within these regions, SRR immunoreactivity
was localized to glia of both the grey and the white matter (Fig. 3B
and C). Previous reports show that SRR immunolabelled glia are
astroctyes, based on colocalization with glial ﬁbrillary acidic protein
(Wolosker et al., 1999a; Xia et al., 2004; Kartvelishvily et al., 2006).
However, we cannot rule out a microglial (Wu & Barger, 2004) or
oligodendrocytic contribution to SRR expression, as a detailed
analysis of glial subtype was beyond the scope of this study. Whilst
our ﬁndings are consistent with a glial localization of SRR, the greater
white than grey matter staining in DPFC (and hippocampus) is at odds
with Wolosker et al. (1999a), who suggest that SRR is enriched in
grey matter astrocytes, as is d-serine (Nagata et al., 1994; Schell et al.,
1995, 1997). However, others report abundant d-serine staining in
the white matter (Kartvelishvily et al., 2006; Williams et al., 2006)
and d-serine concentrations in the white matter of human brain are
equal to or greater than those in grey matter (Kumashiro et al., 1995).
We identiﬁed SRR mRNA and immunoreactivity in the human
and rat cerebellum. Previous studies of cerebellar SRR have been
conﬂicting. Wang & Zhu (2003) could not detect SRR by
immunoblotting in adult mouse cerebellum, in line with reported
low or negligible levels of rodent cerebellar d-serine (Nagata et al.,
1994; Hashimoto et al., 1995a, b; Schell et al., 1995, 1997; Hamase
et al., 1997; Morikawa et al., 2001; Yasuda et al., 2001; Wang &
Zhu, 2003). However, other studies have robustly detected SRR
mRNA (Yoshikawa et al., 2004a) and d-serine immunoreactivity
(Williams et al., 2006) in adult rodent cerebellum. Furthermore,
intracerebroventricular administration of l-serine increases cerebellar
d-serine levels (Hashimoto, 2002), implying that SRR is present
(and active) in the adult cerebellum. Our data indicate that there is a
signiﬁcant and sustained expression of SRR in adult human
cerebellum. It remains to be explained therefore why the majority
of studies cited above suggest cerebellar d-serine levels are
negligible. Possibilities include the SRR being inactive, or that it
is catalysing conversion of a substrate other than l-serine, although
the implications of the Hashimoto (2002) study would not support
this. Another possibility is that SRR is acting as an eliminase
enzyme, breaking down d-serine (Foltyn et al., 2005). Alternatively,
the low d-serine levels seen in cerebellar homogenates may be
misleading. The rapid degradation of d-serine by DAO in the
cerebellum (Morikawa et al., 2001) may in fact show the importance
of tight regulation of cerebellar d-serine levels. Moreover, signiﬁcant
d-serine concentrations may occur at localized sites, such as the
Bergmann glia (Williams et al., 2006), where there is robust SRR
expression, and thereby impact on NMDAR-mediated transmission
in the vicinity.
A ﬁnal aspect of SRR distribution that has remained unclear is
whether SRR is expressed by neurons. It has been suggested to be
exclusively or principally glial, based on studies in the adult primate
(Xia et al., 2004) and developing rat brain and rat neuronal and glial
primary cultures (Wolosker et al., 1999a). However, others demon-
strate SRR expression in mouse neuronal cultures (Yoshikawa et al.,
2006) as well as in cortical neurons of both the developing and the
adult rat brain (Kartvelishvily et al., 2006). We did not identify any
unequivocally SRR-immunoreactive neurons in the DPFC or hippo-
campus. This negative result may reﬂect a species difference, or could
reﬂect a lack of sensitivity of our SRR antibody under the ﬁxation and
processing conditions pertaining in the post-mortem tissue. On the
other hand, we did ﬁnd moderate SRR immunostaining of some
cerebellar Purkinje neurons, consistent with a minor neuronal
contribution to SRR expression in human brain.
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If DAO contributes to NMDAR hypofunction in schizophrenia, then
presumably it does so via enhancement (rather than impairment) of
DAO function, as this will promote d-serine degradation and thence
decreased d-serine occupancy of NMDARs. Our ﬁnding of increased
DAO mRNA in the cerebellum, without any change in SRR
expression, may offer support to this hypothesis, and extends a
preliminary study that also found increased cerebellar DAO mRNA
in schizophrenia (Kapoor et al., 2006). The ﬁndings also support the
emerging view that the cerebellum is an integral part of the circuitry
affected in schizophrenia (e.g. Eastwood et al., 2003 – for reviews
see Katsetos et al., 1997; Andreasen et al., 1998; Konarski et al.,
2005). However, our data are subject to the caveat that although
DAO mRNA was signiﬁcantly increased, DAO immunoreactivity
showed only a trend increase (P ¼ 0.062). Moreover, we did not
determine whether DAO activity is elevated. However, it is
noteworthy that Kapoor et al. (2006) did ﬁnd enhanced cerebellar
DAO activity in schizophrenia to accompany the mRNA elevation. In
this regard, were DAO function increased in schizophrenia the
consequences would be difﬁcult to predict, given the uncertain status
and function of d-serine in the cerebellum outlined above. One
possibility, given our demonstration of DAO and SRR in Bergmann
glia and unchanged cerebellar SRR in schizophrenia, is that a
putative increased DAO could impact Bergmann glia d-serine levels
and thence, speculatively, their regulation of synaptic input to
Purkinje neurons (Cid & Ortega, 1993; Brockhaus & Deitmer, 2002;
Huang & Bordey, 2004).
Increased cerebellar DAO in schizophrenia may arise for one of
several reasons. The fact that DAO mRNA is increased indicates that
the mechanism is likely to involve transcriptional regulation of DAO
expression. This perhaps relates to DAO’s candidacy as a putative
schizophrenia susceptibility gene, as the associated polymorphisms are
all non-coding and so the mechanism of association is probably
through an effect on gene expression, as for other risk genes (Harrison
& Weinberger, 2005; Law et al., 2006). Our sample size was too small
to investigate whether any of the schizophrenia-associated DAO
polymorphisms contributed to the elevated DAO expression seen here
in the disorder. Regardless, as DAO risk alleles are carried by only a
minority of cases and by some control subjects as well, this seems
unlikely to explain a diagnostic difference in DAO expression.
Moreover, as DAO was not increased in the DPFC (present data and
Bendikov et al., 2007) in schizophrenia, one would have to postulate a
region-speciﬁc effect of genotype which, although not unprecedented
(Law et al., 2007), is not parsimonious. Also, DAO genotype does not
predict d-serine levels (Yamada et al., 2005). Instead, increased
cerebellar DAO in schizophrenia may arise as part of the broader
pathophysiological processes, e.g. downstream of other genetic,
developmental or environmental inﬂuences. One example in the last
category is anti-psychotic medication. Although there was no
signiﬁcant effect of haloperidol administration in rats on cerebellar
DAO expression (P ¼ 0.428), the means were  24% higher in the
treated animals, and so it is possible that medication could have
contributed to the elevation seen in patients. An early study reported
that the antipsychotic drug chlorpromazine inhibits DAO activity
(Yagi et al., 1956), but to our knowledge there have been no
subsequent investigations of the effects of antipsychotics on DAO
expression or activity. Future human post-mortem studies of DAO
expression in larger samples with more accurate and extensive
medication histories will help to clarify this issue.
SRR immunoreactivity was increased in schizophrenia, but unlike
DAO, this occurred in the DPFC not the cerebellum, and was not
accompanied by elevated SRR mRNA. The increase was not
hypothesized – in that it would suggest increased rather than
decreased d-serine levels – and its explanation remains unclear. It
may be consequent to other pathophysiological changes; for example,
it may reﬂect an attempted compensatory response to possible disease-
associated reductions in cortical d-serine, or that cortical SRR is
acting as an eliminase (Foltyn et al., 2005), as noted above. This
latter explanation has the attraction of thereby explaining how
d-serine is metabolized in the cortex despite absent DAO activity;
however, it remains controversial as to whether the eliminase
reaction occurs under physiological conditions (Strisovsky et al.,
2005). Mechanistically, the fact that SRR was elevated but not
SRR mRNA suggests regulation at the translational or post-
translational level. One possibility is decreased protein degradation,
as SRR protein levels are regulated by ubiquitin-dependent protea-
somal degradation, a mechanism modulated by the SRR binding
partner Golga3 (Dumin et al., 2006). Whether Golga3 is altered in
schizophrenia is unknown.
Speculation as to the signiﬁcance and the cause of increased DPFC
SRR in schizophrenia should in any event be limited, as variable
ﬁndings have emerged from two other recent studies. First, Steffek
et al. (2006) reported no change in SRR in prefrontal cortex in
schizophrenia, although they did ﬁnd increased SRR in the hippo-
campus; the different demographics of the subjects studied (theirs
were considerably older) may account for the anatomical discrepancy.
In contrast, in a third brain series, Bendikov et al. (2007) found
reduced SRR in frontal cortex (area 10) and hippocampus. Unlike the
other studies, these authors also directly measured d-serine concen-
trations, overcoming some of the interpretational uncertainty. They
replicated the prior reports of reduced cerebrospinal ﬂuid and blood
d-serine in schizophrenia, but did not ﬁnd a reduction in parietal
cortex. Overall, therefore, no consensus has yet emerged from the data
regarding SRR expression, nor d-serine itself, in the cerebral cortex in
schizophrenia.
Limitations of the study
Some measures of DAO expression differed between the two cohorts
of brains studied here (Table 2), even though the basic demographics
are similar (Table 1). The reasons are unknown. However, because the
effect of origin of brains had been seen previously we conducted our
primary data analyses on Z-scored data, allowing the two series to be
combined, generating a larger data set and thence more robust results.
Nevertheless, this variability does raise the issue of the general
applicability of the ﬁndings; inspection of the raw data shows that the
increased cerebellar DAO immunoreactivity and mRNA in schizo-
phrenia, whilst seen in both the London and Oxford series, was more
apparent in the former (Table 2). Interestingly, expression of G72
(DAOA) in schizophrenia has also shown a cohort effect with a larger
change in schizophrenia in one series than the other (Korostishevsky
et al., 2004). It is plausible that expression of DAO, and other genes in
its regulatory pathway, are particularly susceptible to unknown factors
(ranging from genetic variation to peri-mortem confounders) that
differ between brain series. The other main limitation of the present
study is that d-serine itself was not measured, even though most of the
functional implications of altering DAO and SRR expression are
implicitly or explicitly the result of their effect upon d-serine levels. In
our case, tissue availability precluded measurement of d-serine, and
given some reported confounding factors of d-serine measurement in
post-mortem tissue (Kumashiro et al., 1995), other studies may also
have to use the activity and⁄or expression of genes involved in
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ﬂuid (Hashimoto et al., 2003, 2005) as proxy measures.
Conclusions
This study provides the ﬁrst detailed description of the regional and
cellular expression of DAO and SRR in the human brain. The ﬁndings
suggest that d-serine synthesis is primarily glial and occurs in the
cerebellum as well as the cerebral cortex. DAO expression and thence
d-serine catabolism is also glial in the cerebellum, and given the
cellular expression of SRR, may regulate d-serine levels at localized
sites such as the Bergmann glia. However, in the cortex DAO is
neuronal, suggesting a different catabolic route, although the lack of
cortical DAO activity, despite robust expression, remains a paradox.
This study demonstrated increased expression in schizophrenia of
SRR in the DPFC, and of DAO in the cerebellum. The results provide
some support for theories of aberrant d-serine metabolism and
NMDAR dysfunction in the disorder (Olney & Farber, 1995; Coyle,
1996; Tsai et al., 1998; Hashimoto et al., 2003, 2005; Moghaddam,
2003; Heresco-Levy et al., 2005). However any pathophysiological
interpretation remains speculative given the various uncertainties and
inconsistencies dicussed here.
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